Avantium raises €55.5 million as it races to turn its first plant into sales
What's the deal? Dutch renewable-chemistry firm Avantium has launched a €55.45 million rights offering to cover a working-capital shortfall and fund the ramp-up of its flagship FDCA plant in Delfzijl. The post-IPO equity raise, announced in October 2026, follows first-batch production at the facility.
What's the endgame? Avantium uses its YXY technology to convert plant-based sugars into FDCA, a building block for the biobased polyester PEF. The Delfzijl plant — billed as the world's first commercial-scale FDCA site — is designed to produce about 5,000 tonnes a year, and the company now needs to convert that output into commercial deliveries.
Why now? The raise comes 26 years after Avantium spun out of Royal Dutch Shell and nine years after its 2017 IPO on Euronext Amsterdam and Brussels. It follows an €84.8 million equity raise in 2025, as the company shifts from building its plant to funding commercial ramp-up.
By the numbers: First-half 2026 cash, including restricted cash, stood at €23.9 million against an €18.8 million EBITDA loss, with commercial deliveries still expected toward year-end. The new issue price sits 42.7% below the stated theoretical ex-rights price.
What could go wrong? That steep discount underscores both the scale of the funding need and the dilution facing shareholders. Avantium's move from technology developer to industrial producer has proven more expensive and slower than first anticipated, from a construction budget that climbed to roughly €149 million to repeated capital raises.
The signal: By amount, this round sits in the 38th percentile — a modest raise that is less a growth round than a test of whether Avantium can generate sales before needing still more capital.
Read more: bioplasticsnews.com
Image credit: Generated with Gemini
